UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the successful completion of the previously announced transaction to acquire Neurona Therapeutics Inc., including lead asset rezanecel, adding to UCB’s epilepsy portfolio.
Building on UCB’s longstanding heritage in epilepsy and its ambition to deliver differentiated solutions to patients with unmet needs, this acquisition marks a strategic expansion into regenerative medicine and advanced therapies. It further demonstrates UCB’s commitment to inorganic growth and to deliver solutions that go beyond symptomatic management.
The total transaction is valued at up to US $1.15b consisting of a US $650m upfront payment plus up to US $500m in potential future milestone payments. UCB confirms its 2026 financial guidance with revenue expected to grow in a high single-digit to low double-digit percentage range at constant exchange rates (CER). 2026 underlying profitability, measured by adjusted EBITDA, is expected to grow in a high single-digit to mid-teens percentage range at CER.
Source: ucb.com
Bayer has sold a stake in its newly established contraceptives offshoot to global asset management firm Apollo for €3bn ($3.4bn) – allowing the company to access funds without relinquishing overall control of the business.
Mittal succeeds Peter Bains, who completed his tenure as Managing Director & CEO on 30 June 2026, bringing close to three decades of business leadership experience. He joins Syngene from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer.
Evonik is modernizing its active pharmaceutical ingredient production at its Tippecanoe site in Lafayette, Indiana. Over the next five years, the company will invest $100 million in upgrading key equipment used in the manufacture of active pharmaceutical ingredients.
